Ian S Stone1,2, Neil C Barnes2,3, Wai-Yee James1, Dawn Midwinter3, Redha Boubertakh2, Richard Follows3, Leonette John1, Steffen E Petersen2. 1. 1 Department of Respiratory Medicine, The London Chest Hospital, Barts Health NHS Trust, London, United Kingdom. 2. 2 William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; and. 3. 3 Global Respiratory Department, GlaxoSmithKline, Stockley Park, Uxbridge, United Kingdom.
Abstract
RATIONALE: Patients with chronic obstructive pulmonary disease develop increased cardiovascular morbidity with structural alterations. OBJECTIVES: To investigate through a double-blind, placebo-controlled, crossover study the effect of lung deflation on cardiovascular structure and function using cardiac magnetic resonance. METHODS: Forty-five hyperinflated patients with chronic obstructive pulmonary disease were randomized (1:1) to 7 (maximum 14) days inhaled corticosteroid/long-acting β2-agonist fluticasone furoate/vilanterol 100/25 μg or placebo (7-day minimum washout). Primary outcome was change from baseline in right ventricular end-diastolic volume index versus placebo. MEASUREMENTS AND MAIN RESULTS: There was a 5.8 ml/m(2) (95% confidence interval, 2.74-8.91; P < 0.001) increase in change from baseline right ventricular end-diastolic volume index and a 429 ml (P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo. Left ventricular end-diastolic and left atrial end-systolic volumes increased by 3.63 ml/m(2) (P = 0.002) and 2.33 ml/m(2) (P = 0.002). In post hoc analysis, right ventricular stroke volume increased by 4.87 ml/m(2) (P = 0.003); right ventricular ejection fraction was unchanged. Left ventricular adaptation was similar; left atrial ejection fraction improved by +3.17% (P < 0.001). Intrinsic myocardial function was unchanged. Pulmonary artery pulsatility increased in two of three locations (main +2.9%, P = 0.001; left +2.67%, P = 0.030). Fluticasone furoate/vilanterol safety profile was similar to placebo. CONCLUSIONS: Pharmacologic treatment of chronic obstructive pulmonary disease has consistent beneficial and plausible effects on cardiac function and pulmonary vasculature that may contribute to favorable effects of inhaled therapies. Future studies should investigate the effect of prolonged lung deflation on intrinsic myocardial function. Clinical trial registered with www.clinicaltrials.gov (NCT 01691885).
RATIONALE: Patients with chronic obstructive pulmonary disease develop increased cardiovascular morbidity with structural alterations. OBJECTIVES: To investigate through a double-blind, placebo-controlled, crossover study the effect of lung deflation on cardiovascular structure and function using cardiac magnetic resonance. METHODS: Forty-five hyperinflated patients with chronic obstructive pulmonary disease were randomized (1:1) to 7 (maximum 14) days inhaled corticosteroid/long-acting β2-agonist fluticasone furoate/vilanterol 100/25 μg or placebo (7-day minimum washout). Primary outcome was change from baseline in right ventricular end-diastolic volume index versus placebo. MEASUREMENTS AND MAIN RESULTS: There was a 5.8 ml/m(2) (95% confidence interval, 2.74-8.91; P < 0.001) increase in change from baseline right ventricular end-diastolic volume index and a 429 ml (P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo. Left ventricular end-diastolic and left atrial end-systolic volumes increased by 3.63 ml/m(2) (P = 0.002) and 2.33 ml/m(2) (P = 0.002). In post hoc analysis, right ventricular stroke volume increased by 4.87 ml/m(2) (P = 0.003); right ventricular ejection fraction was unchanged. Left ventricular adaptation was similar; left atrial ejection fraction improved by +3.17% (P < 0.001). Intrinsic myocardial function was unchanged. Pulmonary artery pulsatility increased in two of three locations (main +2.9%, P = 0.001; left +2.67%, P = 0.030). Fluticasone furoate/vilanterol safety profile was similar to placebo. CONCLUSIONS: Pharmacologic treatment of chronic obstructive pulmonary disease has consistent beneficial and plausible effects on cardiac function and pulmonary vasculature that may contribute to favorable effects of inhaled therapies. Future studies should investigate the effect of prolonged lung deflation on intrinsic myocardial function. Clinical trial registered with www.clinicaltrials.gov (NCT 01691885).
Authors: V I Peinado; J A Barberá; P Abate; J Ramírez; J Roca; S Santos; R Rodriguez-Roisin Journal: Am J Respir Crit Care Med Date: 1999-05 Impact factor: 21.405
Authors: Ciro Casanova; Claudia Cote; Juan P de Torres; Armando Aguirre-Jaime; Jose M Marin; Victor Pinto-Plata; Bartolome R Celli Journal: Am J Respir Crit Care Med Date: 2004-12-10 Impact factor: 21.405
Authors: M Dambrosio; G Fiore; N Brienza; G Cinnella; M Marucci; V M Ranieri; M Greco; A Brienza Journal: Intensive Care Med Date: 1996-08 Impact factor: 17.440
Authors: F C Sciurba; R M Rogers; R J Keenan; W A Slivka; J Gorcsan; P F Ferson; J M Holbert; M L Brown; R J Landreneau Journal: N Engl J Med Date: 1996-04-25 Impact factor: 91.245
Authors: Carolyn E Come; Miguel J Divo; Raúl San José Estépar; Frank C Sciurba; Gerard J Criner; Nathaniel Marchetti; Steven M Scharf; Zab Mosenifar; Barry J Make; Cesar A Keller; Omar A Minai; Fernando J Martinez; MeiLan K Han; John J Reilly; Bartolome R Celli; George R Washko Journal: Respir Med Date: 2011-08-16 Impact factor: 3.415
Authors: R Graham Barr; David A Bluemke; Firas S Ahmed; J Jeffery Carr; Paul L Enright; Eric A Hoffman; Rui Jiang; Steven M Kawut; Richard A Kronmal; João A C Lima; Eyal Shahar; Lewis J Smith; Karol E Watson Journal: N Engl J Med Date: 2010-01-21 Impact factor: 91.245
Authors: Don D Sin; S F Paul Man; Darcy D Marciniuk; Gordon Ford; Mark FitzGerald; Eric Wong; Ernest York; Rajesh R Mainra; Warren Ramesh; Lyle S Melenka; Eric Wilde; Robert L Cowie; Dave Williams; Wen Q Gan; Roxanne Rousseau Journal: Am J Respir Crit Care Med Date: 2008-02-28 Impact factor: 21.405
Authors: Meilan K Han; Ella A Kazerooni; David A Lynch; Lyrica X Liu; Susan Murray; Jeffrey L Curtis; Gerard J Criner; Victor Kim; Russell P Bowler; Nicola A Hanania; Antonio R Anzueto; Barry J Make; John E Hokanson; James D Crapo; Edwin K Silverman; Fernando J Martinez; George R Washko Journal: Radiology Date: 2011-07-25 Impact factor: 11.105
Authors: Christian M Lo Cascio; Mirja Quante; Eric A Hoffman; Alain G Bertoni; Carrie P Aaron; Joseph E Schwartz; Mark V Avdalovic; Vincent S Fan; Gina S Lovasi; Steven M Kawut; John H M Austin; Susan Redline; R Graham Barr Journal: Chest Date: 2016-12-06 Impact factor: 9.410
Authors: Ozair Rahman; Michael Markl; Pallavi Balte; Haben Berhane; Carmen Blanken; Kenichiro Suwa; Stephen Dashnaw; Oliver Wieben; David A Bluemke; Martin R Prince; Joao Lima; Erin Michos; Bharath Ambale-Venkatesh; Eric A Hoffman; Antoinette S Gomes; Karol Watson; Yanping Sun; James Carr; R Graham Barr Journal: Radiology Date: 2019-07-23 Impact factor: 29.146
Authors: Carrie P Aaron; Eric A Hoffman; Joao A C Lima; Steven M Kawut; Alain G Bertoni; Jens Vogel-Claussen; Mohammadali Habibi; Katja Hueper; David R Jacobs; Ravi Kalhan; Erin D Michos; Wendy S Post; Martin R Prince; Benjamin M Smith; Bharath Ambale-Venkatesh; Chia-Ying Liu; Filip Zemrak; Karol E Watson; Matthew Budoff; David A Bluemke; R Graham Barr Journal: PLoS One Date: 2017-04-20 Impact factor: 3.240
Authors: Denis E O'Donnell; Amany F Elbehairy; Danilo C Berton; Nicolle J Domnik; J Alberto Neder Journal: Front Physiol Date: 2017-02-22 Impact factor: 4.566
Authors: Marc Miravitlles; Nicolas Roche; João Cardoso; David Halpin; Zaurbek Aisanov; Hannu Kankaanranta; Vladimir Kobližek; Paweł Śliwiński; Leif Bjermer; Michael Tamm; Francesco Blasi; Claus F Vogelmeier Journal: Respir Res Date: 2018-01-18